NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy
about
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenibMammalian target of rapamycin inhibitor-associated stomatitisExpert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialThe Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer RegistryUnilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib.NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.Current treatment considerations in metastatic renal cell carcinoma.Histone deacetylases in kidney development: implications for disease and therapy.Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor.mTOR inhibitors: changing landscape of endocrine-resistant breast cancer.PD-1 blockade in renal cell carcinoma: to equilibrium and beyondClinical utility of concurrent single-nucleotide polymorphism microarray on fresh tissue as a supplementary test in the diagnosis of renal epithelial neoplasms.Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma.Modulation of Angiogenesis, Proliferative Response and Apoptosis by β-Sitosterol in Rat Model of Renal Carcinogenesis.Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.Complete response in metastatic renal cell carcinoma after radiotherapy and everolimus: a clinical case and review of the literature.Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2.
P2860
Q21261282-7C099AA9-0C82-4098-B6EF-F8E134C93409Q26825301-1083FBC0-4C90-449C-AAD4-053D2C35B3D9Q30382892-EAED058C-F844-4FBB-AA9D-F918751E67C2Q33750154-C5C9F2C5-E40E-44F1-965A-50CD99D7BA5DQ36486902-20963050-AC69-4077-8B70-8FFC449368BBQ36894689-253A1E85-32BC-47DF-8EAE-FCA1771DC6FBQ37590339-B01B3988-F9A0-47D2-9216-A17164425A34Q37992827-17B211EF-3A54-4F9D-964B-CD031B9BFDEAQ38020758-F8B868F4-A323-4596-BE6E-A7FD9132DB4CQ38110320-088E5207-AA6C-40B5-BC3A-A74524D324A5Q38190114-82157103-81C7-4EB7-A611-A526631C7330Q38283974-FE6341C0-BFAD-445B-BCEA-543A8504C1DEQ38612636-7FD4C956-D0C1-46E6-8394-95E5AB13BD32Q38655156-48A747DF-89E4-45B3-AD07-EDCEBBE71110Q38692489-0E10B861-E4A0-4325-9943-37D8A3E9DA71Q38734141-4825E140-A13A-4BAD-98F2-7C0B650D5358Q38885327-EF17E91B-F3AE-4951-A583-7EB793B99EAAQ39699164-62558DC4-5001-463F-BCDB-466DDB49BCFF
P2860
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
NCCN Task Force report: optimi ...... ith molecular targeted therapy
@ast
NCCN Task Force report: optimi ...... ith molecular targeted therapy
@en
type
label
NCCN Task Force report: optimi ...... ith molecular targeted therapy
@ast
NCCN Task Force report: optimi ...... ith molecular targeted therapy
@en
prefLabel
NCCN Task Force report: optimi ...... ith molecular targeted therapy
@ast
NCCN Task Force report: optimi ...... ith molecular targeted therapy
@en
P2093
P2860
P356
P1476
NCCN Task Force report: optimi ...... ith molecular targeted therapy
@en
P2093
Eric Jonasch
Gary R Hudes
Kim A Margolin
M Dror Michaelson
Michael A Carducci
Rashmi Kumar
Robert J Motzer
Roberto Pili
Sandy Srinivas
P2860
P356
10.6004/JNCCN.2011.0124
P478
P577
2011-02-01T00:00:00Z